While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna (MRNA) stock surged 7% this week following Oracle (ORCL) CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure cancer.

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

In July, the company received $176 million from HHS toward its vaccine efforts. Moderna plans to advance research on the mRNA ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.